As one example of treatment refinement through sustained drug delivery, polymeric nanoparticles supplying BDNF over the course of 5 weeks resulted in a 50% reduction in motor symptoms in two separate models of Parkinson’s disease, and these sustained release systems could be further assessed in the context of neurodegeneration [100,101]. The gene discussed is BDNF; the disease is Parkinson disease.